Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction: A Prospective, Double-blind, Randomized, Placebo-controlled Trial

NCT05477498 is registered in ClinicalTrials.gov with Cantonal Hosptal, Baselland as lead sponsor.

NCT NCT05477498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05477498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction: A Prospective, Double-blind, Randomized, Placebo-controlled Trial
Lead sponsor
Cantonal Hosptal, Baselland
Phase
Phase 4
Overall status
Withdrawn
Start date
December 1, 2021
Completion date
December 31, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with normal ejection fraction, iron-deficiency